🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TRmdkC
@ASCO
#SocialListening #LucidQuest
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TRcFzr
@ASCO
#SocialListening #LucidQuest
Ther Adv Med Oncol: Second‑line mFOLFIRINOX outperformed SOX after gemcitabine+nab‑paclitaxel failure in advanced PDAC (n=113):
• OS 10.4 vs 6.1 mo
• PFS 4.8 vs 2.4 mo
But with higher grade ≥3 AEs.
🔗https://buff.ly/QwPfnx9
#PancreaticCancer #GIOnc
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TRQxmX
@ASCO
#SocialListening #LucidQuest
Ther Adv Med Oncol: Real‑world comparison of mFOLFOX‑6 vs mDCF in metastatic gastric/GEJ cancer (n=493, 25 hospitals):
• PFS: 7 vs 6 mo
• OS: 11 vs 12 mo
• Similar ORR
• Lower grade 3–4 neutropenia/anemia with mFOLFOX‑6
Read: 【🔗https://buff.ly/kUKcGAz 】
#GastricCancer #GIOnc #Chemotherapy
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TRF805
@ASCO
#SocialListening #LucidQuest
Real‑world evidence in Ther Adv Med Onc shows nal‑IRI/5‑FU/LV significantly improves OS in pancreatic adenocarcinoma (28.0 vs 18.3 months) despite higher cost (ICER $33,285/LYG). 🔗https://buff.ly/dOq2XvY
#PancreaticCancer #GIOnc #RealWorldEvidence #HealthEconomics
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TR4sCY
@ASCO
#SocialListening #LucidQuest
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQvxV7
@ASCO
#SocialListening #LucidQuest
Excellent work summarizing #pancsm studies @graokane.bsky.social #GIonc @oncoalert.bsky.social #GIonc
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQkJJF
@ASCO
#SocialListening #LucidQuest
10 Must-Read Posts in GI Oncology This Week
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQYRN4
@ASCO
#SocialListening #LucidQuest
10 Must-Read Posts in GI Oncology This Week
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQPfK2
@ASCO
#SocialListening #LucidQuest
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQFj65
@ASCO
#SocialListening #LucidQuest
✔️ Evidence-aligned, clinician-reviewed
✔️ Ideal for exam preparation & refreshers
✔️ See how you rank on the global leaderboard
#Gastric #GastricCancer #Oncology #OncoIQ #MedicalEducation #GIOnc
GALAXY Study: Postoperative ctDNA as a Prognostic and Predictive Biomarker in Stage II–III Rectal Cancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GALAXY #RectalCancer #GIOnc
ctDNA Dynamics Predict Outcomes in Advanced Gastroesophageal Cancer - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/voices/yan-l...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc #GastroesophagealCancer
10 Must-Read Posts in GI Oncology This Week
oncodaily.com/opinion/10-m...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc
Resectable Esophageal Adenocarcinoma: A Comparative Analysis of Divergent Outcomes With FLOT and CROSS in Trial and Real-World Settings
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EsophagealAdenocarcinoma #GIOnc #FLOT #CROSS
2025 Through the Lens of OncoDaily GI: Building a Focused Voice in Gastrointestinal Oncology
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc #OncoDailyGI
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQ6Y9Q
@ASCO
#SocialListening #LucidQuest
Call for Papers: Special Series on Gastrointestinal Oncology in 2026
oncodaily.com/blog/gastroi...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc
Chronotherapy and Nivolumab in Metastatic Gastric Cancer: Does Infusion Timing Matter?
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Chronotherapy #Nivolumab #GastricCancer #GIOnc
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TQ1J0W
@ASCO
#SocialListening #LucidQuest
10 Must-Read Posts in GI Oncology This Week
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc
🚀 Get the #Oncology buzz from #ASCOGI25!
Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺
Download our full report! http://dlvr.it/TPv5CQ
@ASCO
#SocialListening #LucidQuest
At first glance, Collineau's findings seem to be predictable: FOLFIRINOX is toxic, and OAs are vulnerable. But the deeper issue is whether we are asking the right question. By focusing narrowly on which OA can endure FOLFIRINOX, we risk missing the more relevant point: what is the most tolerable approach to the care of OAs with PDAC, and who truly benefits? The Edison analogy is instructive here. His lasting legacy was not the brightest bulb, but the system that made light usable, safe, and enduring. In PDAC, the lesson is similar: the discovery of an intense regimen is useless unless it is embedded in a system that makes treatment tolerable and meaningful for patients. For OAs, that grid is built through geriatric assessment (GA), supportive interventions (nutrition, prehabilitation, psychosocial support), and integration of palliative care.
From “Who Can Tolerate” to “Who Will Benefit” It is time for all of us to reimagine PDAC care in OA. The central question is no longer “who can tolerate FOLFIRINOX,” but “who will truly benefit?” Answering that requires 1. Routine GA to uncover vulnerabilities 2. Supportive interventions (comorbidity management, exercise, psychosocial support, nutritional support, and palliative integration) to enhance resilience 3. Trial designs that embed tolerability and quality of life as end points that complement response and survival 4. Exploration of objective aging biomarkers (inflammation, senescence, aging clocks, sarcopenia) for future stratification
Really important perspective from Ramy Sedhom on FOLFIRINOX in #panCAN patients >70 years old ("OA"). Even in selected patients who receive this intensive regimen, even w/ preemptive dose reductions, 56% G3 AE or unplanned hospitalization.
ascopubs.org/doi/10.1200/... #JCOOP #GIOnc
